REVERSE MERGER (Tables)

3 Months Ended

Mar. 31, 2018

REVERSE MERGER [Abstract]

Business Acquisition, Pro Forma Information

The following unaudited pro forma information presents the Company's financial results as if the acquisition of Transgenomic had occurred on January 1, 2017 and combines Transgenomic’s unaudited condensed consolidated statement of operations for the three months ended March 31, 2017 with Precipio’s unaudited condensed statement of operations for the three months ended March 31, 2017:

Dollars in thousands, except per share amounts
	For the Three Months Ended March 31,
	2018			2017
Net sales	$	712		$	907
Net loss available to common stockholders	(5,953		)	(2,778		)
Loss per common share	$	(0.47	)	$	(0.42	)